| symbol |
CTRV |
|---|
| 会社名 | Contravir Pharmaceuticals Inc （コントラビ―・ファ―マシュ―ティカルズ） |
|---|
| 分野（sector） |
Health Care
ヘルスケア
|
|---|
| 産業（industry） |
Major Pharmaceuticals
|
|---|
| 業種 |
バイオテクノロジ―_メディカルリサ―チ
医療関連（Health Care）
|
|---|
| 概要 |
事業概要 ContraVir Pharmaceuticals Inc. is focused on curing hepatitis B through the combination of direct and indirect acting antiviral compounds. Its two assets tenofovir exalidex or TXL and CRV431 have complementary mechanisms of action and have shown potential synergy against hepatitis B virus (HBV). TXL is designed to deliver high intrahepatic concentrations of TFV while minimizing off target effects caused by high levels of circulating TFV and has completed a Phase IIa trial. CRV431 the other anti-HBV compound is a next generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against HBV. In vitro and in vivo studies have thus far demonstrated that CRV431 reduces HBV DNA and other viral proteins including surface antigen (HBsAg). コントラビ―・ファ―マシュ―ティカルズは、米国のバイオ医薬品会社。水痘帯状疱疹ウイルスの再活性化によって引き起こされる感染症である帯状疱疹を治療する臨床開発製薬｢FV-100｣に主に焦点を当てる。また水痘帯状疱疹ウイルスの再活性化によって引き起こされる感染症の帯状疱疹のための治療も開発する ContraVir Pharmaceuticals, Inc. engages in the development and commercialization of pleiotropic drug therapy for the treatment of chronic liver disease. It focuses on the development of its product candidate CRV431, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ.
|
|---|
| 本社所在地 | 399 Thornall Street First Floor Edison NJ 08837 USA |
|---|
| 代表者氏名 | Gary S. Jacob ゲイリー・ジェイコブ |
|---|
| 代表者役職名 | Chairman of the Board of Directors |
|---|
| 電話番号 | +1 732-902-4000 |
|---|
| 設立年月日 | 41395 |
|---|
| 市場名 | NASDAQ Small Cap |
|---|
| ipoyear | ―年 |
|---|
| 従業員数 | 20人 |
|---|
| url | www.contravir.com |
|---|
| nasdaq_url | https://www.nasdaq.com/symbol/ctrv |
|---|
| adr_tso | ― |
|---|
| EBITDA | EBITDA（百万ドル） -18.24716 |
|---|
| 終値（lastsale） | 0.57 |
|---|
| 時価総額（marketcap） | 8237593.26 |
|---|
| 時価総額 | 時価総額（百万ドル） 7.94855 |
|---|
| 売上高 | 売上高（百万ドル） 0.00000 |
|---|
| 企業価値(EV) | 企業価値(EV)（百万ドル） 8.22400 |
|---|
| 当期純利益 | 当期純利益（百万ドル） -13.83067 |
|---|
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 ContraVir Pharmaceuticals Inc revenues was not reported. Net loss totaled to $6.7M. Results are not comparable due to year end change. |
|---|